

SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with treatment-naïve neovascular age-related macular degeneration

Vasileios Konidaris,¹ Clemens Lange,^{2,3} Marion R. Munk,^{4,5,6} Paolo Lanzetta,^{7,8} Varun Chaudhary,⁹ Hassiba Oubraham,¹⁰

Tobias Machewitz,¹¹ Helmut Allmeier,¹² Xin Zhang,¹² Clare Bailey,¹³ on behalf of the SPECTRUM study investigators

¹Department of Ophthalmology, University Hospitals of Leicester NHS Trust, Leicester, UK;

²Eye Center, Faculty of Medicine, Albert-Ludwig University Freiburg, Freiburg, Germany; ³Department of Ophthalmology, St. Franziskus Hospital, Münster, Germany;
⁴Augenarzt Praxisgemeinschaft Gutblick AG, Pfäffikon, Switzerland; ⁵Department of Ophthalmology, University Hospital Bern, Switzerland;
⁶Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; ⁷Department of Medicine–Ophthalmology, University of Udine, Italy;
⁸Instituto Europeo di Microchirurgia Oculare (IEMO), Udine, Italy; ⁹Hamilton Regional Eye Institute, St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada; ¹⁰Centre OPHTA-45, Montargis, France; ¹¹Bayer AG, Berlin, Germany; ¹²Bayer Consumer Care AG, Basel, Switzerland;
¹³Department of Ophthalmology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK

Presented at the 2025 Retina World Congress, Fort Lauderdale, FL, USA, May 8–11, 2025

Disclosures

- Vasileios Konidaris: Receives honoraria from AbbVie, Bayer, Novartis, and Roche
 - **CL:** Receives honoraria from Apellis, Bayer, Biogen, and Novartis. MRM: Consulting fees from AbbVie, Allergan, Apellis, Aviceda Therapeutics, Bayer, Boehringer-Ingelheim, Dandelion, Eyepoint, Gensight, Iveric Bio, Isarna Therapeutics, Kubota, Lumithera, Novartis, Ocuterra, Oculis, Ocular Therapeutix, RetinAl, Roche, and Zeiss. PL: Consultant for Aerie Pharmaceuticals, Allergan, Annexon, Apellis, Bausch + Lomb, Bayer, Biogen, Boehringer Ingelheim, Eyepoint Pharmaceuticals, Genentech, I-Care, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Roche. **VC**: Consulting fees from EvePoint; receives grants from Bayer, Novartis, and Roche; serves on advisory boards for Alcon, Roche, Bayer, Novartis, Apellis, and Boehringer Ingelheim. HO: Consultant for AbbVie, Bayer, Novartis, and Roche. TM: Employee of Bayer AG. HA and XZ: Employees of Bayer Consumer Care AG. CB: Receives honoraria from Alimera Sciences, Apellis, Bayer, and Roche; has served on advisory boards for Apellis, Bayer, Boehringer Ingelheim, Janssen, and Roche
- The SPECTRUM study (NCT06075147) was sponsored by Bayer AG (Leverkusen, Germany)

SPECTRUM

- The sponsor participated in the design and conduct of the study, analysis of the data, and preparation of this presentation
- Medical writing support, under the direction of the authors, was provided by ApotheCom and funded by Bayer Consumer Care AG (Basel, Switzerland), in accordance with Good Publication Practice (GPP) guidance (*Ann Intern Med.* 2022;175:1298–1304)



A non-interventional country and global cohort study planned in 18 countries



E 3 E 3 E wmw


2 indications, 4 patient cohorts

Treatment-naïve **nAMD** and previously treated **nAMD** Treatment-naïve **DME** and previously treated **DME**

Primary endpoint: Change in VA from BL to Month 12

Secondary endpoints include: Change in **VA** and **CRT** from BL to Month 6

Number of injections and visits, and safety through Month 6



BL, baseline; CRT, central retinal thickness; DME, diabetic macular edema; nAMD, neovascular age-related macular degeneration; VA, visual acuity.



My Enrollment overview

To date, 632 out of 1200 (53%) planned patients have been enrolled in the treatment-naïve nAMD cohort **United Kingdom** 101 Switzerland 102 Sweden 35 Spain 34 **Republic of Korea** 32 ***** Japan 88 Germany 85 France 24 Denmark 43 Canada 38 Australia 50 0 20 40 60 80 100 120 Number of patients enrolled to date





Early outcomes in the first ~100 patients with treatment-naïve nAMD who had a visit and VA assessment at Week 8

Baseline characteristics: Treatment-naïve nAMD

Interim analysis of patients with a VA assessment at Week 8^a


Total: 114 patients

Mean age: 80.8 ± 7.1 years

Median (min, max) time from nAMD diagnosis: 0.2 (0.0, 21.9) months

Baseline VA: 60.1 ± 17.4 ETDRS letters

Baseline CRT: 358 ± 110 µm




FAS. Percentages may not add up to 100 due to rounding.

^aData are mean ± SD unless otherwise indicated. ^bData on race were collected for Australia, Canada, Germany, Italy, Japan, Portugal, South Korea, Saudi Arabia, Spain, Switzerland, United Arab Emirates, and the UK only. ETDRS, Early Treatment Diabetic Retinopathy Study; FAS, full analysis set; UK, United Kingdom.








FAS, OC. Values have been rounded to the nearest decimal point. ^aPatients with a VA assessment at BL and Week 4. ^bPatients with a VA assessment at BL and Week 8. ^cMean VA change at Week 4 and Week 8 from BL was calculated in patients with a VA assessment at Week 4 and Week 8, respectively; error bars are 95% CI. CI, confidence intervals; OC, observed cases.




CRT through Week 8



FAS, OC. Values have been rounded to the nearest decimal point. ^aPatients with a CRT assessment at BL and Week 4. ^bPatients with a CRT assessment at BL and Week 8. ^cMean CRT change at Week 4 and Week 8 from BL was calculated in patients with a CRT assessment at Week 4 and Week 8, respectively; error bars are 95% CI.



Mean number of aflibercept 8 mg injections in the study eye through Week 8







	Total (N=114)
Ocular TEAEs in the study eye, n (%)	3 (2.6)
Conjunctival hemorrhage	1 (0.9)
Vitreous floaters	1 (0.9)
Not yet coded	1 (0.9)
Non-ocular TEAEs, n (%)	5 (4.4)
Nasopharyngitis	1 (0.9)
Chronic kidney disease	1 (0.9)
Cough	1 (0.9)
Hypertension	3 (2.6)



No serious ocular or non-ocular TEAEs were reported

Early Findings From SPECTRUM Support the Real-World Effectiveness and Safety of Aflibercept 8 mg in the Treatment of Treatment-Naïve nAMD



SPECTRU

2149/4035 patients enrolled in SPECTRUM across 16 countries to date



632/1200 patients enrolled in the treatment-naive nAMD cohort across 11 countries to date



- Improved VA (+3.2 ETDRS letters)
 - Reduction in CRT (-115 μm)



- No new safety signals identified
- No cases of IOI or serious ocular TEAEs



As the **first global real-world study of aflibercept 8 mg**, early findings from SPECTRUM will help **inform clinical management** of treatment-naïve nAMD in patients receiving aflibercept 8 mg

Month 6 data will be presented in 2025, with Month 12 and Month 24 analyses on track